Log in to your Inderes Free account to see all free content on this page.
Nightingale Health
2.72
EUR
-2.86 %
Corporate customer
HEALTH
First North Finland
Medical Equipment & Services
Health Care
4,537 following
-2.86%
-9.93%
-5.56%
-16.31%
+22.52%
+119.71%
-13.15%
-
-47.18%
Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.
Read moreMarket cap
165.72M EUR
Turnover
119.26K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage

Head of Nordic ER Development, Analyst
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
6.3.
2025
Interim report Q2'25
Risk
Business risk
Valuation risk
Low
High
ShowingAll content types
Nightingale Health and Enigma Genomics enter into collaboration to sell the Nightingale Remote Health Check in the MENA region
Nightingale Health published new disease risk assessments
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Nightingale Health announces the performance metrics of its latest generation disease risk assessments to be rolled out in Singapore and the United States
Conversion of Nightingale Health Plc's EMP shares to Series B shares
Nightingale Health Plc - Managers' Transactions - Olli Karhi
Nightingale Health Plc appoints Lago Kapital as liquidity provider
Nightingale Health Plc: Subscription of Series B shares with option rights
Study published in Nature Communications: Nightingale Health outperforms genetic testing in chronic disease risk detection and makes the promise of preventative health a reality

Life Science Companies as Investments | Life Science Night Dec. 2, 2024
Nightingale opens Singapore laboratory
Nightingale Health announces opening of its Singapore laboratory
Nightingale explores transfer to Nasdaq Helsinki main list and OTC trading in the US
Inside information: Nightingale Health is investigating the transfer of its B shares to the Main Market of Nasdaq Helsinki and adding the OTCQX market as an additional trading venue in the U.S.
Nightingale completes necessary regulatory approvals in Singapore
Nightingale Health Asia achieves ISO 13485:2016 certification and completes regulatory readiness to launch its blood testing service in Singapore
